# BIO-TECHNE Corp: financial statements, quarterly

TECH · Nasdaq · CIK 842023 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/tech.md) · [Financials](/companies/tech/financials.md) · [Filings](/companies/tech/filings.md) · [Insiders](/companies/tech/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tech/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [277](/filings/0001558370-24-014439.md) | [273](/filings/0001558370-25-000689.md) | [303](/filings/0001558370-25-006990.md) | [306 d](/filings/0001104659-26-100322.md) | [289](/filings/0001104659-25-107053.md) | [297](/filings/0001104659-26-010335.md) | [316](/filings/0001104659-26-056302.md) | [317 d](/filings/0001104659-26-100322.md) | [287](/filings/0001104659-25-107053.md) | [296](/filings/0001104659-26-010335.md) | [311](/filings/0001104659-26-056302.md) | [321 d](/filings/0001104659-26-100322.md) |
| Cost of revenue | $m | [91.7](/filings/0001558370-24-014439.md) | [96.0](/filings/0001558370-25-000689.md) | [98.8](/filings/0001558370-25-006990.md) | [103 d](/filings/0001104659-26-100322.md) | [106](/filings/0001104659-25-107053.md) | [103](/filings/0001104659-26-010335.md) | [102](/filings/0001104659-26-056302.md) | [118 d](/filings/0001104659-26-100322.md) | [98.4](/filings/0001104659-25-107053.md) | [105](/filings/0001104659-26-010335.md) | [103](/filings/0001104659-26-056302.md) | [110 d](/filings/0001104659-26-100322.md) |
| Gross profit | $m | [185](/filings/0001558370-24-014439.md) | [177](/filings/0001558370-25-000689.md) | [205](/filings/0001558370-25-006990.md) | [203 d](/filings/0001104659-26-100322.md) | [183](/filings/0001104659-25-107053.md) | [194](/filings/0001104659-26-010335.md) | [215](/filings/0001104659-26-056302.md) | [199 d](/filings/0001104659-26-100322.md) | [188](/filings/0001104659-25-107053.md) | [191](/filings/0001104659-26-010335.md) | [208](/filings/0001104659-26-056302.md) | [211 d](/filings/0001104659-26-100322.md) |
| Selling, general and administrative | $m | [105](/filings/0001558370-24-014439.md) | [116](/filings/0001558370-25-000689.md) | [112](/filings/0001558370-25-006990.md) | [134 d](/filings/0001104659-26-100322.md) | [119](/filings/0001104659-25-107053.md) | [121](/filings/0001104659-26-010335.md) | [151](/filings/0001104659-26-056302.md) | [197 d](/filings/0001104659-26-100322.md) | [116](/filings/0001104659-25-107053.md) | [114](/filings/0001104659-26-010335.md) | [109](/filings/0001104659-26-056302.md) | [113 d](/filings/0001104659-26-100322.md) |
| Operating income | $m | [55.9](/filings/0001558370-24-014439.md) | [38.0](/filings/0001558370-25-000689.md) | [67.0](/filings/0001558370-25-006990.md) | [45.8 d](/filings/0001104659-26-100322.md) | [40.0](/filings/0001104659-25-107053.md) | [47.4](/filings/0001104659-26-010335.md) | [38.7](/filings/0001104659-26-056302.md) | [(23.9) d](/filings/0001104659-26-100322.md) | [47.7](/filings/0001104659-25-107053.md) | [54.5](/filings/0001104659-26-010335.md) | [75.5](/filings/0001104659-26-056302.md) | [74.3 d](/filings/0001104659-26-100322.md) |
| Interest expense | $m | [4.9](/filings/0001558370-23-018018.md) | [4.3](/filings/0001558370-24-000862.md) | [4.0](/filings/0001558370-24-006803.md) | [2.5 d](/filings/0001104659-26-100322.md) | [2.2](/filings/0001104659-25-107053.md) | [2.1](/filings/0001104659-26-010335.md) | [2.0](/filings/0001104659-26-056302.md) | [2.2 d](/filings/0001104659-26-100322.md) | [2.9](/filings/0001104659-25-107053.md) | [2.2](/filings/0001104659-26-010335.md) | [2.4](/filings/0001104659-26-056302.md) | [2.1 d](/filings/0001104659-26-100322.md) |
| Income tax | $m | [(1.4)](/filings/0001558370-24-014439.md) | [5.9](/filings/0001558370-25-000689.md) | [12.0](/filings/0001558370-25-006990.md) | [1.1 d](/filings/0001104659-26-100322.md) | [6.6](/filings/0001104659-25-107053.md) | [8.0](/filings/0001104659-26-010335.md) | [15.7](/filings/0001104659-26-056302.md) | [(5.2) d](/filings/0001104659-26-100322.md) | [9.8](/filings/0001104659-25-107053.md) | [12.8](/filings/0001104659-26-010335.md) | [20.2](/filings/0001104659-26-056302.md) | [16.1 d](/filings/0001104659-26-100322.md) |
| Net income | $m | [51.0](/filings/0001558370-24-014439.md) | [27.5](/filings/0001558370-25-000689.md) | [49.1](/filings/0001558370-25-006990.md) | [40.6 d](/filings/0001558370-25-011716.md) | [33.6](/filings/0001104659-25-107053.md) | [34.9](/filings/0001104659-26-010335.md) | [22.6](/filings/0001104659-26-056302.md) | [(17.7) d](/filings/0001558370-25-011716.md) | [38.2](/filings/0001104659-25-107053.md) | [38.0](/filings/0001104659-26-010335.md) | [51.0](/filings/0001104659-26-056302.md) | [54.6 d](/filings/0001104659-26-100322.md) |
| Diluted EPS | $ per share | [0.31](/filings/0001558370-24-014439.md) | [0.17](/filings/0001558370-25-000689.md) | [0.31](/filings/0001558370-25-006990.md) | not reported | [0.21](/filings/0001104659-25-107053.md) | [0.22](/filings/0001104659-26-010335.md) | [0.14](/filings/0001104659-26-056302.md) | not reported | [0.24](/filings/0001104659-25-107053.md) | [0.24](/filings/0001104659-26-010335.md) | [0.32](/filings/0001104659-26-056302.md) | not reported |
| Basic EPS | $ per share | [0.32](/filings/0001558370-24-014439.md) | [0.17](/filings/0001558370-25-000689.md) | [0.31](/filings/0001558370-25-006990.md) | not reported | [0.21](/filings/0001104659-25-107053.md) | [0.22](/filings/0001104659-26-010335.md) | [0.14](/filings/0001104659-26-056302.md) | not reported | [0.25](/filings/0001104659-25-107053.md) | [0.24](/filings/0001104659-26-010335.md) | [0.33](/filings/0001104659-26-056302.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [149](/filings/0001558370-23-018018.md) | [130](/filings/0001558370-24-000862.md) | [140](/filings/0001558370-24-006803.md) | [152](/filings/0001558370-25-011716.md) | [188](/filings/0001558370-24-014439.md) | [178](/filings/0001558370-25-000689.md) | [141](/filings/0001558370-25-006990.md) | [162](/filings/0001104659-26-100322.md) | [145](/filings/0001104659-25-107053.md) | [173](/filings/0001104659-26-010335.md) | [210](/filings/0001104659-26-056302.md) | [265](/filings/0001104659-26-100322.md) |
| Current assets | $m | [591](/filings/0001558370-23-018018.md) | [591](/filings/0001558370-24-000862.md) | [611](/filings/0001558370-24-006803.md) | [617](/filings/0001558370-25-011716.md) | [649](/filings/0001558370-24-014439.md) | [635](/filings/0001558370-25-000689.md) | [627](/filings/0001558370-25-006990.md) | [608](/filings/0001104659-26-100322.md) | [610](/filings/0001104659-25-107053.md) | [637](/filings/0001104659-26-010335.md) | [688](/filings/0001104659-26-056302.md) | [744](/filings/0001104659-26-100322.md) |
| Total assets | $m | [2,755](/filings/0001558370-23-018018.md) | [2,731](/filings/0001558370-24-000862.md) | [2,721](/filings/0001558370-24-006803.md) | [2,704](/filings/0001558370-25-011716.md) | [2,736](/filings/0001558370-24-014439.md) | [2,670](/filings/0001558370-25-000689.md) | [2,644](/filings/0001558370-25-006990.md) | [2,558](/filings/0001104659-26-100322.md) | [2,526](/filings/0001104659-25-107053.md) | [2,523](/filings/0001104659-26-010335.md) | [2,551](/filings/0001104659-26-056302.md) | [2,587](/filings/0001104659-26-100322.md) |
| Current liabilities | $m | [128](/filings/0001558370-23-018018.md) | [135](/filings/0001558370-24-000862.md) | [150](/filings/0001558370-24-006803.md) | [159](/filings/0001558370-25-011716.md) | [142](/filings/0001558370-24-014439.md) | [161](/filings/0001558370-25-000689.md) | [169](/filings/0001558370-25-006990.md) | [176](/filings/0001104659-26-100322.md) | [145](/filings/0001104659-25-107053.md) | [140](/filings/0001104659-26-010335.md) | [153](/filings/0001104659-26-056302.md) | [164](/filings/0001104659-26-100322.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [1,998](/filings/0001558370-25-006990.md) | [1,964](/filings/0001558370-25-006990.md) | [2,014](/filings/0001558370-25-006990.md) | [2,069](/filings/0001104659-26-100322.md) | [2,139](/filings/0001558370-25-006990.md) | [2,078](/filings/0001558370-25-006990.md) | [2,018](/filings/0001558370-25-006990.md) | [1,919](/filings/0001104659-26-100322.md) | [1,966](/filings/0001104659-26-056302.md) | [2,011](/filings/0001104659-26-010335.md) | [2,085](/filings/0001104659-26-056302.md) | [2,108](/filings/0001104659-26-100322.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [59.4](/filings/0001558370-24-014439.md) | [83.1 d](/filings/0001558370-25-000689.md) | [81.0 d](/filings/0001558370-25-006990.md) | [75.5 d](/filings/0001104659-26-100322.md) | [63.9](/filings/0001104659-25-107053.md) | [84.3 d](/filings/0001104659-26-010335.md) | [41.1 d](/filings/0001104659-26-056302.md) | [98.2 d](/filings/0001104659-26-100322.md) | [27.6](/filings/0001104659-25-107053.md) | [82.4 d](/filings/0001104659-26-010335.md) | [86.7 d](/filings/0001104659-26-056302.md) | [95.4 d](/filings/0001104659-26-100322.md) |
| Capital expenditure | $m | [13.6](/filings/0001558370-24-014439.md) | [14.9 d](/filings/0001558370-25-000689.md) | [16.4 d](/filings/0001558370-25-006990.md) | [18.0 d](/filings/0001104659-26-100322.md) | [9.2](/filings/0001104659-25-107053.md) | [6.8 d](/filings/0001104659-26-010335.md) | [10.1 d](/filings/0001104659-26-056302.md) | [4.9 d](/filings/0001104659-26-100322.md) | [5.4](/filings/0001104659-25-107053.md) | [5.9 d](/filings/0001104659-26-010335.md) | [9.1 d](/filings/0001104659-26-056302.md) | [8.5 d](/filings/0001104659-26-100322.md) |
| Dividends paid | $m | [12.7](/filings/0001558370-24-014439.md) | [12.6 d](/filings/0001558370-25-000689.md) | [12.6 d](/filings/0001558370-25-006990.md) | [12.6 d](/filings/0001104659-26-100322.md) | [12.7](/filings/0001104659-25-107053.md) | [12.7 d](/filings/0001104659-26-010335.md) | [12.6 d](/filings/0001104659-26-056302.md) | [12.4 d](/filings/0001104659-26-100322.md) | [12.4](/filings/0001104659-25-107053.md) | [12.5 d](/filings/0001104659-26-010335.md) | [12.5 d](/filings/0001104659-26-056302.md) | [12.5 d](/filings/0001104659-26-100322.md) |
| Share repurchases | $m | not reported | not reported | [0.0 d](/filings/0001558370-25-006990.md) | [0.0 d](/filings/0001104659-26-100322.md) | not reported | not reported | [100 d](/filings/0001104659-26-056302.md) | [100 d](/filings/0001104659-26-100322.md) | [0.0](/filings/0001104659-25-107053.md) | [0.0 d](/filings/0001104659-26-010335.md) | [0.0 d](/filings/0001104659-26-056302.md) | [41.7 d](/filings/0001104659-26-100322.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [162](/filings/0001558370-23-018018.md) | [162](/filings/0001558370-24-000862.md) | [162](/filings/0001558370-24-006803.md) | [162](/filings/0001558370-24-014439.md) | [160](/filings/0001558370-25-000689.md) | [160](/filings/0001558370-25-006990.md) | [161](/filings/0001104659-25-107053.md) | [161](/filings/0001104659-26-010335.md) | [159](/filings/0001104659-26-056302.md) | [156](/filings/0001104659-25-107053.md) | [157](/filings/0001104659-26-010335.md) | [157](/filings/0001104659-26-056302.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 156,818,238 at 2026-08-17, from the cover of the [10-K filed 2026-08-24](/filings/0001104659-26-100322.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.